Analysts Set Expectations for BioNTech FY2024 Earnings

BioNTech SE (NASDAQ:BNTX) – Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($5.24) for the year. HC Wainwright currently has a “Buy” rating and a $150.00 price target on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at ($3.42) EPS, Q2 2025 earnings at ($3.50) EPS, Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at ($6.43) EPS.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period last year, the firm posted $1.90 earnings per share.

A number of other research firms also recently weighed in on BNTX. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. Truist Financial started coverage on BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price target for the company. Canaccord Genuity Group restated a “buy” rating and set a $171.44 price objective on shares of BioNTech in a research report on Tuesday. Morgan Stanley reduced their target price on BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, BMO Capital Markets raised their price target on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.73.

BioNTech Trading Down 2.8 %

BNTX opened at $97.46 on Wednesday. The company’s 50 day moving average price is $116.18 and its two-hundred day moving average price is $113.04. The firm has a market capitalization of $23.37 billion, a price-to-earnings ratio of -46.41 and a beta of 0.30. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

Institutional Trading of BioNTech

Several large investors have recently made changes to their positions in the company. Planning Capital Management Corp raised its stake in BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after buying an additional 450 shares during the period. Jones Financial Companies Lllp lifted its stake in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after buying an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. grew its holdings in shares of BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after buying an additional 700 shares during the last quarter. Allianz SE bought a new stake in shares of BioNTech during the fourth quarter worth about $90,000. Finally, GAMMA Investing LLC increased its position in shares of BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after acquiring an additional 300 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.